Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials

Clinical and Molecular Predictors of PD-L1 Expression in Non–Small-Cell Lung Cancer: Systematic Review and Meta-analysis

(2018) Fausto Petrelli et al.   Clinical Lung Cancer

Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)

(2018) Yingcheng Wu et al.   INTERNATIONAL JOURNAL OF CANCER

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

(2018) James Larkin et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

(2018) Fabio Conforti et al.   LANCET ONCOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-Angiogenics: Current Situation and Future Perspectives

(2018) Katja Zirlik et al.   Oncology Research and Treatment

Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy

(2018) Imerio Capone et al.   Frontiers in Immunology

Rare Genetic Diseases with Defects in DNA Repair: Opportunities and Challenges in Orphan Drug Development for Targeted Cancer Therapy

(2018) Sonali Bhattacharjee et al.   Cancers

Receptor Tyrosine Kinase-Targeted Cancer Therapy

(2018) Toshimitsu Yamaoka et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer

(2017) Ramaswamy Govindan et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Yoon-Koo Kang et al.   LANCET

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

(2017) Michele Maio et al.   LANCET ONCOLOGY

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

(2017) Andrea Botticelli et al.   Oncotarget

Hormonal Modulation of Dendritic Cells Differentiation, Maturation and Function: Implications for the Initiation and Progress of Systemic Autoimmunity

(2016) Juan Pablo Mackern-Oberti et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients

(2016) Yuan Yuan et al.   CANCER CELL

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

(2016) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

(2016) F Stephen Hodi et al.   LANCET ONCOLOGY

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

(2016) Danny N. Khalil et al.   Nature Reviews Clinical Oncology

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances

(2016) J. L. Messerschmidt et al.   ONCOLOGIST

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment

(2016) Andrea Botticelli et al.   Oncotarget

Estrogen receptors regulate innate immune cells and signaling pathways

(2015) Susan Kovats   CELLULAR IMMUNOLOGY

Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study

(2015) Emanuele Crocetti et al.   EUROPEAN JOURNAL OF CANCER

Erratum: Gender differences in incidence and outcomes of urothelial and kidney cancer

(2015) Ilaria Lucca et al.   Nature Reviews Urology

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sex- and gender-specific disparities in colorectal cancer risk

(2015) Sung-Eun Kim   WORLD JOURNAL OF GASTROENTEROLOGY

Sex Differences in Infectious Diseases-Common but Neglected

(2014) J. van Lunzen et al.   JOURNAL OF INFECTIOUS DISEASES

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Sex Differences in the Gut Microbiome Drive Hormone-Dependent Regulation of Autoimmunity

(2013) J. G. M. Markle et al.   SCIENCE

SeXX matters in immunity

(2013) J.G. Markle et al.   TRENDS IN IMMUNOLOGY

Deleterious Effect of CTLA4-Ig on a Treg-Dependent Transplant Model

(2012) L. V. Riella et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Sex and gender differences in health

(2012) Vera Regitz-Zagrosek   EMBO REPORTS

Gender Differences in Cancer Susceptibility: An Inadequately Addressed Issue

(2012) M. Tevfik Dorak et al.   Frontiers in Genetics

Autoimmune disease and gender: Plausible mechanisms for the female predominance of autoimmunity

(2011) Olga L. Quintero et al.   JOURNAL OF AUTOIMMUNITY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE